P.2.b.015 Lu AA21004: a novel potential treatment for mood disorders

@article{Moore2008P2b015LA,
  title={P.2.b.015 Lu AA21004: a novel potential treatment for mood disorders},
  author={Nicholas Moore and Benny Bang-Andersen and Lise T{\o}ttrup Brennum and K. Fredriksen and Sandy Hogg and Arne M{\o}rk and Tine Bryan Stensb{\o}l and Hua Zhong and Connie S{\'a}nchez and D. G. Smith},
  journal={European Neuropsychopharmacology},
  year={2008},
  volume={18}
}

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

Treatment with 5 mg and 10 mg Lu AA21004 for 6 wk was efficacious and well tolerated in patients with MDD and the most common AEs were nausea, headache, hyperhidrosis, and dry mouth.

A Review of Antidepressant Therapy in Primary Care: Current Practices and Future Directions

  • S. Kennedy
  • Psychology, Medicine
    The primary care companion for CNS disorders
  • 2013
Doctors in primary care should have expertise in working with a number of current antidepressant approaches and an awareness of new and emerging treatments, although differences in symptoms and comorbid conditions among individual depressed patients present a challenge for the physician providing individualized treatment.

Pd-catalyzed thiocarbonylation with stoichiometric carbon monoxide: scope and applications.

A general protocol for the Pd-catalyzed thiocarbonylation of aryl iodides with stoichiometric carbon monoxide has been established employing a catalytic system composed of Pd(OAc)(2) and DPEphos with

A Randomized Trial on the Acute and Steady‐State Effects of a New Antidepressant, Vortioxetine (Lu AA21004), on Actual Driving and Cognition

Vortioxetine did not impair driving, cognitive, or psychomotor performance after single or multiple doses, and most of these effects disappeared after multiple doses of mirtazapine.

Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects.

A well-grounded and reliable relationship between the plasma concentration of the drug and the occupancy of the receptor ⁄ transporter is a powerful tool to investigate the mechanism of action of a new drug and to guide dose selection in CNS drugs.

Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.

In conscious rats, 5m significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment, indicating that 5m is a novel multimodal serotonergic compound, and5m is currently in clinical development for major depressive disorder.

Role of 5-HT3 Receptors in the Antidepressant Response

Major advances in the research of 5-HT3 receptor's roles in neuropsychiatric disorders are reported, with special emphasis on mood and anxiety disorders.